Skip to content

Want To Lose 50 Pounds In Two Weeks? Try Wegovy® Semaglutide

Wegovy® is a medication that contains semaglutide and is used for weight management. Semaglutide, the active ingredient in Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Originally developed as a treatment for type 2 diabetes, semaglutide has also been approved for use in a higher-dose formulation for weight management.

Wegovy is intended for individuals with obesity or overweight who have weight-related conditions, such as high blood pressure, type 2 diabetes, or high cholesterol. It is administered as a once-weekly injection and is typically used in conjunction with a reduced-calorie diet and increased physical activity.

As a GLP-1 receptor agonist, semaglutide helps regulate blood sugar levels and also has effects on appetite and food intake. It works by mimicking the effects of the natural hormone GLP-1, which is involved in the regulation of glucose metabolism and food intake.

WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine that may help adults and children aged ≥12 years with obesity (BMI ≥30 for adults, BMI ≥ 95th percentile for age and sex for children), or some adults with excess weight (BMI ≥27) (overweight) who also have weight-related medical problems to help them lose weight and keep it off. Wegovy® should be used with a reduced calorie meal plan and increased physical activity.

wegovy 2

Does Wegovy Really Work For Weight Loss?

Wegovy® (semaglutide) works as a weight management medication, and its mechanism of action is related to its role as a glucagon-like peptide-1 (GLP-1) receptor agonist. Here’s how Wegovy works:

GLP-1 Receptor Agonism: Semaglutide, the active ingredient in Wegovy, acts as an agonist (activator) of the GLP-1 receptors. GLP-1 is a naturally occurring hormone that plays a role in regulating blood sugar levels and appetite.

Blood Sugar Regulation: GLP-1 receptor agonists, including semaglutide, enhance insulin secretion from the pancreas in response to meals. This helps to lower blood sugar levels by facilitating the uptake of glucose by cells.

Appetite Regulation: Semaglutide affects the brain’s appetite centers, leading to a reduction in appetite and food intake. This effect can contribute to weight loss in individuals using Wegovy.

Slowed Gastric Emptying: Wegovy can slow down the emptying of the stomach, leading to a feeling of fullness and satisfaction with smaller amounts of food.

Potential Increase in Energy Expenditure: GLP-1 receptor agonists may also have an impact on energy expenditure, contributing to weight loss.

It’s important to note that while Wegovy can be effective in promoting weight loss, its use should be part of a comprehensive approach to weight management that includes a reduced-calorie diet and increased physical activity.

Does Wegovy Really Work For Weight Loss

Basic Information About Wegovy® Semaglutide

INDICATIONS AND USAGE

WEGOVY® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:

•adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

•pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) .

Limitations of Use:

•WEGOVY® should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist.

•The safety and efficacy of coadministration with other products for weight loss have not been established.

•WEGOVY® has not been studied in patients with a history of pancreatitis.

wegovy
wegovy 3

DOSAGE AND ADMINISTRATION

•Administer WEGOVY® once weekly, on the same day each week, at any time of day, with or without meals.

•Inject subcutaneously in the abdomen, thigh or upper arm.

•In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY® treatment.

•Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 2.4 mg is reached.

•The maintenance dosage of WEGOVY® in adults is either2.4 mg (recommended) or 1.7 mg once-weekly.

•The maintenance dosage of WEGOVY® in pediatric patients aged 12 years and older is 2.4 mg weekly.

Lose Weight

Join WhatsApp

Join whatsapp to assess your obesity status and learn how to lose weight quickly

whatsapp code

Patient Selection

Adult Patients

Select adult patients for WEGOVY® treatment as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management based on their BMI. Table 1 presents a chart for determining BMI based on height and weight. BMI is calculated by dividing weight (in kilograms)by height (in meters) squared.

BMI Conversion Chart
age BMI

Pediatric Patients Aged 12 Years and Older

Select pediatric patients aged 12 years and older for WEGOVY® treatment as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management based on the BMI values provided in Tables 1 and 2. Table 1 presents a chart for determining BMI based on height and weight. Table 2 presents BMI cut-offs for obesity in pediatric patients aged 12 years and older, determined based on the CDC age- and sex-specific growth charts.

Important Monitoring and Administration Instructions

In patients with type 2 diabetes, monitor blood glucose prior to starting WEGOVY® and during WEGOVY® treatment.

Prior to initiation of WEGOVY®, train patients on proper injection technique. Refer to the accompanying Instructions for Use for complete administration instructions with illustrations.

Inspect WEGOVY® visually prior to each injection. Only use if solution is clear, colorless, and contains no particles.

Administer WEGOVY® once weekly, on the same day each week, at any time of day, with or without meals.

Inject WEGOVY® subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without dose adjustment.

Recommended Dosage in Pediatric Patients Aged 12 Years and Older

Dosage Initiation and Escalation:

Initiate WEGOVY® according to the dosage escalation schedule in Table 4 to minimize gastrointestinal adverse reactions.

If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.

The 0.25 mg. 0.5 mg, and 1 mg once-weekly dosages are initiation and escalation dosages and are not approved as maintenance dosages for chronic weight management.

Maintenance Dosage:

The maintenance dosage of WEGOVY® in pediatric patients aged 12 years and older is 2.4 mg once-weekly.

Dosage Modifications for Adverse Reactions:

•If patients do not tolerate the 2.4 mg once-weekly maintenance dosage, the maintenance dosage may be reduced to 1.7 mg once-weekly.

•Discontinue WEGOVY® if the patient cannot tolerate the 1.7 mg once-weekly dosage.

Recommended Dosage Regimen for Pediatric
Recommended Dosage Regimen for Adults

Recommended Dosage in Adults

Dosage Initiation and Escalation:

Initiate WEGOVY® with a dosage of 0.25 mg injected subcutaneously once-weekly. Then follow the dose escalation schedule presented in Table 3 to minimize gastrointestinal adverse reactions.

•If patients do not tolerate a dose during dosage escalation consider delaying dosage escalation for 4 weeks.

•The 0.25 mg, 0.5 mg, and 1 mg once-weekly dosages are initiation and escalation dosages and are not approved as maintenance dosages for chronic weight management.

Maintenance Dosage:

•The maintenance dosage of WEGOVY® in adults is either 2.4 mg (recommended) or 1.7 mg once-weekly. Consider treatment response and tolerability when selecting the maintenance dosage.

Recommended Dosage in Pediatric Patients Aged 12 Years and Older

Dosage Initiation and Escalation:

Initiate WEGOVY® according to the dosage escalation schedule in Table 4 to minimize gastrointestinal adverse reactions.

If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.

The 0.25 mg. 0.5 mg, and 1 mg once-weekly dosages are initiation and escalation dosages and are not approved as maintenance dosages for chronic weight management.

Maintenance Dosage:

The maintenance dosage of WEGOVY® in pediatric patients aged 12 years and older is 2.4 mg once-weekly.

Dosage Modifications for Adverse Reactions:

•If patients do not tolerate the 2.4 mg once-weekly maintenance dosage, the maintenance dosage may be reduced to 1.7 mg once-weekly.

•Discontinue WEGOVY® if the patient cannot tolerate the 1.7 mg once-weekly dosage.

Recommendations Regarding Missed Dose

If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY® as soon as possible. If one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose. Resume dosing on the regularly scheduled day of the week.

If 2 or more consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY® and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment.

DOSAGE FORMS AND STRENGTHS

•Injection: pre-filled, single-dose pen that delivers doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg.

CONTRAINDICATIONS

•Personal or family history of MTC or in patients with MEN2.

•Known hypersensitivity to semaglutide or any of the excipientsin WEGOVY®.

Lose Weight

Join WhatsApp

Join whatsapp to assess your obesity status and learn how to lose weight quickly

whatsapp code

WARNINGS AND PRECAUTIONS

•Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.

•Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.

•Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

•Acute Kidney Injury: Has occurred. Monitor renal function when initiating or escalating doses of WEGOVY® in patients reporting severe adverse gastrointestinal reactions orin those with renal impairment reporting severe adverse gastrointestinal reactions.

•Hypersensitivity Reactions: Anaphylactic reactions andangioedema have been reported postmarketing. Discontinue WEGOVY® if suspected and promptly seek medical advice.

•Diabetic Retinopathy Complications in Patients with Type2 Diabetes: Has been reported in trials with semaglutide. Patients with a history of diabetic retinopathy should be monitored.

•Heart Rate Increase: Monitor heart rate at regular intervals.

•Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. Discontinue WEGOVY® if symptoms develop.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) in adults or pediatric patients aged 12 years and older are: nausea,diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.

Adult Adverse Reactions

Adverse Reactions in Clinical Trials in Adults with Obesity or Overweight

WEGOVY® 2.4 mg Subcutaneous Weekly Dosage

WEGOVY® was evaluated for safety in 3 randomized, doubleblind, placebo-controlled trials that included 2,116 adult patients with overweight or obesity treated with 2.4 mg WEGOVY® for up to 68 weeks and a 7 week off drug follow-up period.

Adverse Reactions in a Clinical Trial of Pediatric Patients Aged 12 Years and Older with Obesity

WEGOVY® was evaluated in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pediatric patients aged 12 years and older with obesity.

12 year old adverse reaction

DRUG INTERACTIONS

WEGOVY® delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution.

USE IN SPECIFIC POPULATIONS

•Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue WEGOVY® .

•Females and Males of Reproductive Potential: Discontinue WEGOVY® at least 2 months before a planned pregnancy because of the long half-life of semaglutide.

How To Use Wegovy® Correctly

Do not use WEGOVY® if you have the following conditions

you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

you have had a serious allergic reaction to semaglutide or any of the ingredients in WEGOVY®. See the end of this Medication Guide for a complete list of ingredients in WEGOVY®. Symptoms of a serious allergic reaction include:

• swelling of your face, lips, tongue or throat

• fainting or feeling dizzy

• problems breathing or swallowing

• very rapid heartbeat

• severe rash or itching

Lose Weight

Join WhatsApp

Join whatsapp to assess your obesity status and learn how to lose weight quickly

whatsapp code

How should you use WEGOVY®?

Read the Instructions for Use that comes with WEGOVY®.

Use WEGOVY® exactly as your healthcare provider tells you to.

Your healthcare provider should show you how to use WEGOVY® before you use it for the first time.

WEGOVY® is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Do not inject WEGOVY® into a muscle (intramuscularly) or vein (intravenously).

Change (rotate) your injection site with each injection. Do not use the same site for each injection.

Use WEGOVY® 1 time each week, on the same day each week, at any time of the day.

Start WEGOVY® with 0.25 mg per week in your first month. In your second month, increase your weekly dose to 0.5 mg. In the third month, increase your weekly dose to 1 mg. In the fourth month, increase your weekly dose to 1.7 mg. In the fifth month onwards, your healthcare provider may either maintain your dose at 1.7 mg weekly or increase your weekly dose to 2.4mg.

If you need to change the day of the week, you may do so as long as your last dose of WEGOVY® was given 2 or more days before.

If you miss a dose of WEGOVY® and the next scheduled dose is more than 2 days away (48 hours), take the missed dose as soon as possible. If you miss a dose of WEGOVY® and the next schedule dose is less than 2 days away (48 hours), do not administer the dose. Take your next dose on the regularly scheduled day.

If you miss doses of WEGOVY® for more than 2 weeks, take your next dose on the regularly scheduled day or call your healthcare provider to talk about how to restart your treatment.

You can take WEGOVY® with or without food.

If you take too much WEGOVY®, you may have severe nausea, severe vomiting and severe low blood sugar. Call your healthcare provider or go to the nearest hospital emergency room right away if you experience any of these symptoms.

Points to note when using WEGOVY®

Before using WEGOVY®, tell your healthcare provider if you have any other medical conditions, including if you:

• have or have had problems with your pancreas or kidneys.

• have type 2 diabetes and a history of diabetic retinopathy.

• have or have had depression or suicidal thoughts, or mental health issues.

• are pregnant or plan to become pregnant. WEGOVY® may harm your unborn baby. You should stop using WEGOVY® 2 months before you plan to become pregnant.

• Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who use WEGOVY® during pregnancy. The purpose of this registry is to collect information about the health of you and your baby.

• are breastfeeding or plan to breastfeed. It is not known if WEGOVY® passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using WEGOVY®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. WEGOVY® may affect the way some medicines work and some medicines may affect the way WEGOVY® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or

insulin. WEGOVY® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What Is The Actual Cost Of Wegovy?

As of the information provided, the list price of Wegovy is $1,349.02 for a package containing four pens, each pre-filled with a single dose. This amount is for approximately a month’s worth of the medication. Without insurance, the cost breaks down to $269.80 per week or $16,188.24 per year.

It’s important to note that actual out-of-pocket costs for individuals can vary based on factors such as insurance coverage, discounts, and other pricing arrangements. Additionally, manufacturer savings programs or patient assistance programs may be available to help reduce the cost for eligible individuals.

Lose Weight

Join WhatsApp

Join whatsapp to assess your obesity status and learn how to lose weight quickly

whatsapp code

How Can You Get Wegovy Semaglutide For Weight Loss?

To obtain Wegovy (semaglutide) for weight loss, follow these general steps:

Steps 1: Consultation with Healthcare Provider

Schedule an appointment with your healthcare provider, such as a primary care physician or an endocrinologist.

Discuss your weight loss goals, medical history, and any existing health conditions.

Your healthcare provider will evaluate whether Wegovy is a suitable option for you based on your individual health profile.

Steps 2: Prescription

If your healthcare provider determines that Wegovy is appropriate for you, they will provide a prescription.

The prescription will specify the dosage and administration instructions.

Steps 3: Pharmacy

Take the prescription to a pharmacy to have it filled.

Confirm with your pharmacy whether they have Wegovy in stock and inquire about any potential insurance coverage.

Steps 4: Insurance Coverage

Check with your insurance provider to understand the coverage for Wegovy. Some insurance plans may cover weight loss medications, while others may not.

Steps 5: Patient Assistance Programs

Investigate whether the manufacturer of Wegovy offers any patient assistance programs or savings cards that could help reduce the out-of-pocket costs.

Steps 6: Follow-Up Appointments

Schedule follow-up appointments with your healthcare provider to monitor your progress, assess any side effects, and make adjustments to the treatment plan if necessary.

How Can You Get Wegovy Semaglutide

Are There Any Alternatives To Wegovy?

there are several other medications that may be considered as alternatives to Wegovy (semaglutide) for weight management. It’s important to note that the choice of medication depends on individual health factors, preferences, and the guidance of a healthcare professional.

Orlistat (Xenical, Alli): Orlistat works by blocking the absorption of fat in the digestive system. It is available in both prescription (Xenical) and over-the-counter (Alli) forms.

Phentermine-Topiramate (Qsymia): This combination medication suppresses appetite and is approved for weight management. It is available in extended-release capsules.

Liraglutide (Saxenda): Similar to semaglutide, liraglutide is a GLP-1 receptor agonist used for weight management. It is administered by injection, typically once a day.

Naltrexone-Bupropion (Contrave): This combination medication affects the central nervous system to reduce appetite and increase metabolism.

Phentermine (Adipex-P, Lomaira): Phentermine is an appetite suppressant that is often used for short-term weight loss.

Zepbound™ (tirzepatide): Both Zepbound™ (tirzepatide) and Wegovy (semaglutide) are medications used for weight management, and they belong to the class of glucagon-like peptide-1 (GLP-1) receptor agonists.

Lose Weight

Join WhatsApp

Join whatsapp to assess your obesity status and learn how to lose weight quickly

whatsapp code

References: https://www.novo-pi.com/wegovy.pdf#guide